• Cytomed Therapeutics received a Nasdaq notice citing non-compliance with the US$ 1.00 minimum bid-price rule.
• The stock closed below US$ 1.00 for 30 consecutive business days, triggering a listing deficiency under Nasdaq rules.
• The company has until April 5, 2027 to regain compliance by holding a closing bid price of at least US$ 1.00 for 10 straight sessions.
• Failure to cure by the deadline could lead to delisting risk, though an additional 180-day extension may be available.
• A reverse stock split is a potential remedy if needed during any second compliance period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytomed Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610091630PRIMZONEFULLFEED9843017) on October 09, 2026, and is solely responsible for the information contained therein.